Creative Medical Technology Holdings (CELZ) FCF Margin (2017 - 2025)
Creative Medical Technology Holdings' (CELZ) quarterly FCF Margin came in at 64585.13% in Q4 2025, up 39940.0% year-over-year from N/an in Q4 2024, and down 21.74% quarter-over-quarter from 53051.17% in Q1 2025.
Powered by 
Analysis
Creative Medical Technology Holdings (CELZ) FCF Margin (2017 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported FCF Margin for 9 consecutive years, with 64585.13% the latest figure, recorded in Q4 2025.
- On a quarterly basis, FCF Margin rose 39940.0% year-over-year to 64585.13% in Q4 2025; TTM through Jun 2026 was 196723.93%, a 10196717.0% decrease from a year earlier, with the FY2025 full-year figure at 97607.42%, down 4941385.0% from the prior year.
- FCF Margin was 64585.13% for Q4 2025 at Creative Medical Technology Holdings, down from 53051.17% in the prior quarter.
- Over five years, FCF Margin peaked at 1587.82% in Q3 2022 and troughed at 64984.53% in Q4 2024.
- A 5-year average of 27095.56% and a median of 18837.0% in 2024 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin surged 232007 bps in 2022 and plunged 4385839 bps in 2023, its largest moves.
- Over 5 years, FCF Margin stood at 1714.05% in 2021, then plunged by 1026 bps to 19307.71% in 2022, then tumbled by 227 bps to 63166.1% in 2023, then fell by 3 bps to 64984.53% in 2024, then rose by 1 bps to 64585.13% in 2025.
- The last three FCF Margin figures came in at 64585.13% (Q4 2025), 53051.17% (Q1 2025), and 64984.53% (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 59.74% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | -826.50% |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -66.71% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -3.46% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | -497.31% |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | -13,981.63% |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | -33.11% |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 48.98% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 18.67% |
| 10 | Creative Medical Technology Holdings | 1.48 Mn | 1.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -64,585.13% |
| Mar 31, 2025 | -53,051.17% |
| Dec 31, 2024 | -64,984.53% |
| Jun 30, 2024 | -18,366.30% |
| Dec 31, 2023 | -63,166.10% |
| Sep 30, 2023 | -21,742.05% |
| Dec 31, 2022 | -19,307.71% |
| Sep 30, 2022 | -1,587.82% |
| Mar 31, 2022 | -10,512.62% |
| Dec 31, 2021 | -1,714.05% |
| Sep 30, 2021 | -3,907.89% |
| Jun 30, 2021 | -2,221.39% |
| Dec 31, 2020 | 325.63% |
| Sep 30, 2020 | -225.99% |
| Jun 30, 2020 | -438.02% |
| Mar 31, 2020 | -463.95% |
| Dec 31, 2019 | 5,737.09% |
| Sep 30, 2019 | -623.10% |
| Jun 30, 2019 | -534.68% |
| Mar 31, 2019 | -537.43% |